Form D · Pharmaceuticals

EMERAMED Ltd

Dublin, L2 · CIK 0001623416

Offering snapshot reported Feb 12, 2018 · SEC filing

Reported sold
Yet to sell
Indefinite offering
Investors reported
0
Form D · investor count
Minimum accepted
$1K
Reported outside-investor minimum
First sale
Yet to occur
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Feb 12, 2018InitialYet to sellNo comparison0SEC filing
Nov 15, 2016Initial$274,217No comparison6SEC filing
Jun 17, 2016Amendment$3,585,788$811,848vs Feb 29, 201657SEC filing
Feb 29, 2016Initial$2,773,940No comparison32SEC filing
Oct 20, 2015Amendment$2,044,545No comparison26SEC filing
Oct 30, 2014InitialYet to sellNo comparison0SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
Yes
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-305347

Source: Form D, filed Feb 12, 2018. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Boyd E Haley Director, Executive
David C Kennedy Director
Ragnar Klingberg Director, Executive
Christian Krog Jensen Director
J Todd Renner Director, Executive
J. Todd Renner Director, Executive
Kathryn M Wachsman Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
Trinity House Charleston Road, Ranelagh
Dublin, L2, 6